Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

What I post comes from historical Due Diligence. Who needs to try manipulating a downturn? The CEO at Algernon Pharmaceuticals is doing a bang up job of pushing the stock further into the depths of hell (Dante's Inferno) all by his lonesome. I'm just telling the story as I see it unfolding. If one methodically follows the math of Algernon's separate, unequal, and rapidly expanding trading platforms (AGN/PF, AGN Neuro, AGN.RT), it wouldn't be difficult to understand the combined and ever-changing numbers. It'd be interesting to see if anyone else anywhere has numbers explaining otherwise.

Otherwise _____________.

Does anyone here believe that by increasing the share count with massive dilution somehow will increase the share price? For goodness sake...with all the previous pie in the sky talk about uplisting to NASDAQ, your leaders are now selling your company out from under your feet for 25 Cents Canadian. That's 18 Cents USD not including matching warrants. What you can surely expect moving forward is more(au) monkeying around with coffer draining ($$$) - non performance driven - Salaries, Ferrari size Bonuses, Free stock giveaways, and ineffective big ego feeding "Marketing".

The headliner "2022 Wonderland Psychedelic Conference" comes to mind. How'd that work out for your bottomline?

I have a theory. Maybe it takes a true exit from Dante's Inferno to be capable of explaining a Scorched Earth experience without fear or favor? Then again, personally I've always called it how I see it.

On Another Note:

The last report by stock analyst Dr. Andre Uddin at Research Capital (aka Smackie Mackie), he stated AGN is a $25 CAD per share "Speculative Buy" based on the Idiopathic Pulmonary Fibrosis (IPF) data not the Chronic Cough data.

In the near term, parent company Algernon is not actively pursuing IPF. They're not actively pursuing CKD. They're not actively pursuing Cancer. They're hoping to get funding for a standalone Chronic Cough study as the DMT stuff hangs in the balance. It begs the question of where does Uddin's analysis stand now considering all of Algernon's flip flopping since his last analysis back in July 2022?

Split adjusted, Uddin's buy rating is $6.25 CAD/$4.50 USD per share. It doesn't get the 100:1 pre-split shares to a minimum break even price of $7.50 USD.

My best guess is Uddin will not update his analysis anytime soon. To date, none of his AGN buy ratings have been accurate. However, I give him credit for telling the truth about Algernon's failed COVID-19 Topline data (ZERO Efficacy). It was data the CEO (Moreau) continued to pump/pedal and refuse to admit it was a failure.

In contrast, Uddin stated in black and white that Ifenprodil would not advance to a Phase 3 clinical trial and that's Egg Zack Lee what happened irrespective of Moreau jumping up and down for several months thereafter as if a Phase 3 COVID-19 clinical trial was imminent.

Would Algernon Pharmaceuticals care to share their FDA "End of Phase 2 Meeting Request" findings with all shareholders? Let's see (in black and white) how it aligns with the CEO's reasons for not advancing Ifenprodil to a Phase 3 clinical trial.

Ifenprodil was convincingly labeled a "65% Chance Of Success" by your CEO (Christopher Moreau) and CSO (Dr. Mark Williams, PhD, MBA). If only they had conjured up some mathematical magic for Ifenprodil having a 100% Chance of Success, WHO KNOWS, Algernon's market cap may have topped a GAZILLION DOLLAR$?

Algernon Pharmaceuticals Inc - Home Of The Wizards Of Odds




M$